CLINICAL FEATURES AND TREATMENT OUTCOMES IN NON-HODGKIN?S LYMPHOMA IN CHILDHOOD: 24 YEARS EXPERIENCE OF A SINGLE CENTER
(Abstract release date: 05/21/15)
EHA Library. Akici F. 06/12/15; 102791; PB1662
Disclosure(s): Kanuni Sultan Suleyman Training and Research HospitalPediatric Hematology-Oncology Clinic
Ferhan Akici
Contributions
Contributions
Abstract
Abstract: PB1662
Type: Publication Only
Background
Non-Hodgkin's lymphomas (NHL) of childhood and adolescence are a heterogeneous group of malign diseases originating from the lymphoid cells. NHL usually responds to the polychemotherapy and survival rates in NHL have increased significantly in the last decades.
Aims
This study aims was to evaluate and compare the demographic data and treatment results of childrens with NHL treated and therapeutic efficacy of modified NHL German Berlin Frankfurt Munster (BFM) protocols in our center retrospectively.
Methods
115 children (79 male, 36 female) from January 1990 to September 2014, new diagnosed with NHL were enrolled to the study. The patients were stratified by risk factors and treated either with a modified B-nonB NHL BFM-90 (before 2004) or BFM-95 (after 2004) protocols. (Until September 1993, lymphoblast?c patients recived LSAL2, non lymphoblast?c NHL patients recived COMP ) and the use of 1 or 3 g/m2 of methotrexate instead of 5 g/m2/24 h was the only important modification in BFM-90 protocol.
Results
Demographic results: the median age 7 years(range: 3-14.5years) were treated in the center with median 81 months follow-up. Histopathologic subtypes were:24 lymphoblast?c, 11 anaplastic large cell, 80 nonlymphoblastic Burkitt/diffüz B cell. 3 patients (3%) were in stage I, 19 patients (17%) in stage II, 64 (56%) in stage III, and 29(24%) in stage IV. The most common initial primary tumor location sites were abdomen (58%), head and neck (18%) and thorax (15%).The median LDH level at diagnosis was 790U/L(224-10300). Treatment results: 32 patients (24 progressive disease, 6 toxicity, 2 seconder neoplasm)died.7 patients were follow-up. The 10-year overall survival (OS) for all patients was 72%, and event-free survival (EFS) was 67% respectively. 10 year survival was 100,89,76,51% in stage I,II,III, and IV. The 10-year OS rates in modified BFM-90 and in BFM-95 protocols were 66% and 84%; the 10-year EFS rates in these 2 protocols were 60% and 84%, respectively (p=0.061 for OS, p=0.049 for EFS).Survival rates were significantly higher in patients receiving modified BFM regimen, than in ones COMP and LSA2L2
Summary
Survival rates in the whole group are in parallel with advances attained in the world in NHL.The significantly higher survival rates achieved in patients with advanced stage non lymphoblastic patients receiving modified BFM(1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advences in supportive care in the last decade.
Session topic: Publication Only
Type: Publication Only
Background
Non-Hodgkin's lymphomas (NHL) of childhood and adolescence are a heterogeneous group of malign diseases originating from the lymphoid cells. NHL usually responds to the polychemotherapy and survival rates in NHL have increased significantly in the last decades.
Aims
This study aims was to evaluate and compare the demographic data and treatment results of childrens with NHL treated and therapeutic efficacy of modified NHL German Berlin Frankfurt Munster (BFM) protocols in our center retrospectively.
Methods
115 children (79 male, 36 female) from January 1990 to September 2014, new diagnosed with NHL were enrolled to the study. The patients were stratified by risk factors and treated either with a modified B-nonB NHL BFM-90 (before 2004) or BFM-95 (after 2004) protocols. (Until September 1993, lymphoblast?c patients recived LSAL2, non lymphoblast?c NHL patients recived COMP ) and the use of 1 or 3 g/m2 of methotrexate instead of 5 g/m2/24 h was the only important modification in BFM-90 protocol.
Results
Demographic results: the median age 7 years(range: 3-14.5years) were treated in the center with median 81 months follow-up. Histopathologic subtypes were:24 lymphoblast?c, 11 anaplastic large cell, 80 nonlymphoblastic Burkitt/diffüz B cell. 3 patients (3%) were in stage I, 19 patients (17%) in stage II, 64 (56%) in stage III, and 29(24%) in stage IV. The most common initial primary tumor location sites were abdomen (58%), head and neck (18%) and thorax (15%).The median LDH level at diagnosis was 790U/L(224-10300). Treatment results: 32 patients (24 progressive disease, 6 toxicity, 2 seconder neoplasm)died.7 patients were follow-up. The 10-year overall survival (OS) for all patients was 72%, and event-free survival (EFS) was 67% respectively. 10 year survival was 100,89,76,51% in stage I,II,III, and IV. The 10-year OS rates in modified BFM-90 and in BFM-95 protocols were 66% and 84%; the 10-year EFS rates in these 2 protocols were 60% and 84%, respectively (p=0.061 for OS, p=0.049 for EFS).Survival rates were significantly higher in patients receiving modified BFM regimen, than in ones COMP and LSA2L2
Summary
Survival rates in the whole group are in parallel with advances attained in the world in NHL.The significantly higher survival rates achieved in patients with advanced stage non lymphoblastic patients receiving modified BFM(1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advences in supportive care in the last decade.
Session topic: Publication Only
Abstract: PB1662
Type: Publication Only
Background
Non-Hodgkin's lymphomas (NHL) of childhood and adolescence are a heterogeneous group of malign diseases originating from the lymphoid cells. NHL usually responds to the polychemotherapy and survival rates in NHL have increased significantly in the last decades.
Aims
This study aims was to evaluate and compare the demographic data and treatment results of childrens with NHL treated and therapeutic efficacy of modified NHL German Berlin Frankfurt Munster (BFM) protocols in our center retrospectively.
Methods
115 children (79 male, 36 female) from January 1990 to September 2014, new diagnosed with NHL were enrolled to the study. The patients were stratified by risk factors and treated either with a modified B-nonB NHL BFM-90 (before 2004) or BFM-95 (after 2004) protocols. (Until September 1993, lymphoblast?c patients recived LSAL2, non lymphoblast?c NHL patients recived COMP ) and the use of 1 or 3 g/m2 of methotrexate instead of 5 g/m2/24 h was the only important modification in BFM-90 protocol.
Results
Demographic results: the median age 7 years(range: 3-14.5years) were treated in the center with median 81 months follow-up. Histopathologic subtypes were:24 lymphoblast?c, 11 anaplastic large cell, 80 nonlymphoblastic Burkitt/diffüz B cell. 3 patients (3%) were in stage I, 19 patients (17%) in stage II, 64 (56%) in stage III, and 29(24%) in stage IV. The most common initial primary tumor location sites were abdomen (58%), head and neck (18%) and thorax (15%).The median LDH level at diagnosis was 790U/L(224-10300). Treatment results: 32 patients (24 progressive disease, 6 toxicity, 2 seconder neoplasm)died.7 patients were follow-up. The 10-year overall survival (OS) for all patients was 72%, and event-free survival (EFS) was 67% respectively. 10 year survival was 100,89,76,51% in stage I,II,III, and IV. The 10-year OS rates in modified BFM-90 and in BFM-95 protocols were 66% and 84%; the 10-year EFS rates in these 2 protocols were 60% and 84%, respectively (p=0.061 for OS, p=0.049 for EFS).Survival rates were significantly higher in patients receiving modified BFM regimen, than in ones COMP and LSA2L2
Summary
Survival rates in the whole group are in parallel with advances attained in the world in NHL.The significantly higher survival rates achieved in patients with advanced stage non lymphoblastic patients receiving modified BFM(1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advences in supportive care in the last decade.
Session topic: Publication Only
Type: Publication Only
Background
Non-Hodgkin's lymphomas (NHL) of childhood and adolescence are a heterogeneous group of malign diseases originating from the lymphoid cells. NHL usually responds to the polychemotherapy and survival rates in NHL have increased significantly in the last decades.
Aims
This study aims was to evaluate and compare the demographic data and treatment results of childrens with NHL treated and therapeutic efficacy of modified NHL German Berlin Frankfurt Munster (BFM) protocols in our center retrospectively.
Methods
115 children (79 male, 36 female) from January 1990 to September 2014, new diagnosed with NHL were enrolled to the study. The patients were stratified by risk factors and treated either with a modified B-nonB NHL BFM-90 (before 2004) or BFM-95 (after 2004) protocols. (Until September 1993, lymphoblast?c patients recived LSAL2, non lymphoblast?c NHL patients recived COMP ) and the use of 1 or 3 g/m2 of methotrexate instead of 5 g/m2/24 h was the only important modification in BFM-90 protocol.
Results
Demographic results: the median age 7 years(range: 3-14.5years) were treated in the center with median 81 months follow-up. Histopathologic subtypes were:24 lymphoblast?c, 11 anaplastic large cell, 80 nonlymphoblastic Burkitt/diffüz B cell. 3 patients (3%) were in stage I, 19 patients (17%) in stage II, 64 (56%) in stage III, and 29(24%) in stage IV. The most common initial primary tumor location sites were abdomen (58%), head and neck (18%) and thorax (15%).The median LDH level at diagnosis was 790U/L(224-10300). Treatment results: 32 patients (24 progressive disease, 6 toxicity, 2 seconder neoplasm)died.7 patients were follow-up. The 10-year overall survival (OS) for all patients was 72%, and event-free survival (EFS) was 67% respectively. 10 year survival was 100,89,76,51% in stage I,II,III, and IV. The 10-year OS rates in modified BFM-90 and in BFM-95 protocols were 66% and 84%; the 10-year EFS rates in these 2 protocols were 60% and 84%, respectively (p=0.061 for OS, p=0.049 for EFS).Survival rates were significantly higher in patients receiving modified BFM regimen, than in ones COMP and LSA2L2
Summary
Survival rates in the whole group are in parallel with advances attained in the world in NHL.The significantly higher survival rates achieved in patients with advanced stage non lymphoblastic patients receiving modified BFM(1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advences in supportive care in the last decade.
Session topic: Publication Only
{{ help_message }}
{{filter}}